RNA-Binding Protein Screens: Design, Readouts and Hit Prioritization

An RBP screen can start from either side:

• • Protein-centric: perturb many RBPs (CRISPR knockout, knockdown, or overexpression) and measure a phenotype or an RNA readout.
• • RNA-centric: purify a protein and identify the RNAs it binds (RIP, CLIP variants, RNA interactome capture).

The first answers "which RBP matters for this phenotype". The second answers "what does this RBP bind". Neither answers the other's question, and a paper claiming mechanism usually needs both.

This article is about designing each, reading their outputs honestly, and deciding which hits deserve the expensive follow-up. The post-transcriptional evidence hierarchy is set out in the pillar; this piece is the screening companion.

Two practical notes. Pooled screens are efficient for viability and sorting phenotypes and poor for subtle expression changes. CLIP-based methods are the opposite: rich per-protein detail, one protein per experiment.

Perturbation strength. Complete knockouts of essential RBPs are lost from pooled libraries, so results are biased toward non-essential genes. Inducible systems or partial knockdown reveal a different hit set.

Readout distance from the mechanism. A viability screen reports a phenotype several steps removed from RNA binding. If the question is post-transcriptional, consider a readout closer to the event — 3′UTR reporter stability, splicing ratio, or a specific transcript's abundance.

Replicate structure and library quality. Standard: multiple guides per gene, low MOI, adequate representation, non-targeting controls at a few percent.

Context. RBP function is highly cell-type-dependent; a screen in a convenient line may miss the biology relevant to your tissue.

The right-hand column is the interpretive boundary. Binding is a necessary component of function, not evidence of it: a CLIP peak at a site with no measurable consequence after RBP perturbation is a binding event, and that is worth reporting as such.

A useful discipline: for each prioritized binding site, state the predicted consequence (stability, splicing, export, translation) and the assay that would detect it. Hits without a testable prediction should not enter the follow-up queue.

Rank by evidence, not by score:

1. Reproducibility across guides or replicates — the first filter, and the one that removes most false positives.
2. Effect size in a mechanism-adjacent readout, not only in a distant phenotype.
3. Concordance between binding and consequence — the RBP binds the transcript and perturbing the RBP changes that transcript.
4. Motif or structural support — a recognizable binding element near the site.
5. Context relevance — expression in the tissue of interest, and a plausible disease link.

A hit that satisfies 1, 3, and 5 is a strong candidate even without a motif match; a hit with only a motif match is a prediction.

The follow-up sequence that converts a screen hit into a mechanism:

• • Validate the perturbation (protein loss, not just mRNA).
• • Confirm binding at the candidate transcript (CLIP or a targeted RIP with controls).
• • Map the functional element — mutate the binding site, or use a tethering assay to test sufficiency.
• • Measure the intervening step — stability, splicing, or translation, matched to the predicted mechanism.
• • Rescue with wild-type but not binding-deficient protein.

The last step is what separates "this RBP regulates this transcript" from "this RBP binds this transcript and something else changed".

EDITGENE builds the follow-up systems: isogenic binding-site mutations, tethering lines for sufficiency tests, RBP knockout and degron lines with protein-level validation, and stability or splicing readouts matched to the predicted mechanism.

Tell us the RBP and the target transcript. Contact EDITGENE to request a project consultation or quote.

Screen performance depends on library design, cell type, essentiality of the targets, and readout choice; hit rates in the literature are not transferable between systems.

Binding data establish association. Functional claims require perturbation of the RBP or the binding site, an intervening assay, and rescue.

• • Van Nostrand EL, et al. A large-scale binding and functional map of human RNA-binding proteins. Nature. 2020;583:711–719.
• • Baltz AG, et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Molecular Cell. 2012;46:674–690.
• • Hentze MW, et al. A brave new world of RNA-binding proteins. Nature Reviews Molecular Cell Biology. 2018;19:327–341.
• • Gebauer F, et al. RNA-binding proteins in human genetic disease. Nature Reviews Genetics. 2021;22:185–198.